Predictors of adherence among Alzheimer's disease patients receiving oral therapy

被引:50
作者
Borah, Bijan [2 ]
Sacco, Patricia [3 ]
Zarotsky, Victoria [1 ]
机构
[1] I3 Innovus, Calabasas, CA 91302 USA
[2] I3 Innovus, Eden Prairle, MN USA
[3] Novartis Pharmaceut, E Hanover, NJ USA
关键词
Alzheimer's disease; Donepezil; Galantamine; Medication adherence; Memantine; Rivastigmine; HEALTH-CARE COSTS; MEDICATION ADHERENCE; ECONOMIC COSTS; RIVASTIGMINE; DONEPEZIL; DRUG; IMPACT; NONCOMPLIANCE; ASSOCIATION; PERSISTENCE;
D O I
10.1185/03007995.2010.493788
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Treatment effectiveness depends upon administering medications as prescribed, and adherence is critical for Alzheimer's disease (AD) patients to receive optimal benefit from therapy. The objective of this study was to investigate factors associated with adherence to AD oral medications. Methods: This retrospective claims analysis identified AD patients who initiated oral AD therapy (rivastigmine, donepezil, galantamine, or memantine) between January 1, 2006 and December 31, 2007 from a large US health plan. Patient baseline characteristics were assessed during the 6-month pre-index period; outcomes were assessed during the 1-year post-index period. Pill burden was measured as a count of unique units of medication/day. Adherence was measured by medication possession ratio (MPR), with MPR >= 80% defined as adherent. Multivariate logistic regression was used to assess how potential covariates affect adherence probability. Results: A total of 3091 AD patients (36% male; mean age 80 [8.25 SD]) were identified. Only 58% of patients were adherent to oral AD medications. Compared to patients 575 years, patients >= 86 years were likely to be more adherent (OR 1.401, p<0.001). Other factors found to be positively associated with the probability of adherence to AD medications were male gender (OR - 1.175, p<0.05), overall pill burden (OR - 1.192, p<0.001), and a lower formulary tier status of the AD medication (OR = 1.332, p<0.001). Conclusion: Among the several variables assessed, being male, >= 86 years of age, having a greater overall daily pill burden, or using a lower formulary tier AD medication was associated with better adherence to oral AD medication in patients diagnosed with AD. The database had no information on caregiver support, medication management interventions, or use of adherence aids that may have affected adherence in this cohort, yet, a substantial proportion of patients (42%) remained non-adherent. A better understanding of the causes of non-adherence is necessary, and methods to improve adherence, such as transdermal medications and educational programs, should be considered.
引用
收藏
页码:1957 / 1965
页数:9
相关论文
共 48 条
[1]  
[Anonymous], [No title captured]
[2]   Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil [J].
Auriacombe, S ;
Pere, JJ ;
Loria-Kanza, Y ;
Vellas, B .
CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (03) :129-138
[3]   Economic cost of Alzheimer disease in Israel [J].
Beeri, MS ;
Werner, P ;
Adar, Z ;
Davidson, M ;
Noy, S .
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2002, 16 (02) :73-80
[4]   Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy [J].
Benner, JS ;
Pollack, MF ;
Smith, TW ;
Bullano, MF ;
Willey, VJ ;
Williams, SA .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (14) :1468-1475
[5]   Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs [J].
Borah, Bijan J. ;
Huang, Xingyue ;
Zarotsky, Victoria ;
Globe, Denise .
CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (06) :1365-1377
[6]   Switching cholinesterase inhibitor therapy in Alzheimer's disease - donepezil to rivastigmine, is it worth it? [J].
Bullock, R ;
Connolly, C .
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2002, 17 (03) :288-289
[7]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[8]   A systematic review of the associations between dose regimens and medication compliance [J].
Claxton, AJ ;
Cramer, J ;
Pierce, C .
CLINICAL THERAPEUTICS, 2001, 23 (08) :1296-1310
[9]  
Cummings JL, 2002, AM FAM PHYSICIAN, V65, P2525
[10]  
Emre M, 2002, INT J CLIN PRACT, P64